On November 12, Moderna, Inc. recorded an Intraday Decline 3.03% in Regular Trading, trading at $243.525 per share, with turnover of $836 million.

The clearest recent catalyst was a sharp split in analyst valuation views: Rothschild & Co Redburn lifted its price target only slightly to $82 from $81, contrasting with Piper Sandler's earlier increase to $305, as the stock pulled back after a strong earnings-driven rally.

Background context shows Moderna, Inc. reported quarterly EPS of $0.38 on revenue of $1.313 billion, up 29% year over year, and raised full-year revenue growth guidance to 15% to 25%. Even so, options activity has recently reflected caution, including a long-dated $11.67 million bear put spread, underscoring continued investor disagreement on how sustainable the recent re-rating may be.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)